{"id":3586,"date":"2025-04-08T15:29:57","date_gmt":"2025-04-08T12:29:57","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3586"},"modified":"2025-04-08T15:29:58","modified_gmt":"2025-04-08T12:29:58","slug":"new-drug-submission-for-agamree-vamorolone-accepted-for-priority-review-by-health-canada-for-the-treatment-of-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/new-drug-submission-for-agamree-vamorolone-accepted-for-priority-review-by-health-canada-for-the-treatment-of-duchenne-muscular-dystrophy\/","title":{"rendered":"Salud Canad\u00e1 acepta la solicitud de AGAMREE (vamorolone) para su revisi\u00f3n prioritaria para el tratamiento de la distrofia muscular de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Catalyst Pharmaceuticals ha anunciado que Health Canada ha aceptado su Solicitud de Nuevo Medicamento (NDS) para AGAMREE (vamorolone) con revisi\u00f3n prioritaria para el tratamiento de la distrofia muscular de Duchenne (DMD). De aprobarse, AGAMREE se convertir\u00eda en la primera y \u00fanica terapia aprobada por Health Canada para la DMD, con posible autorizaci\u00f3n de comercializaci\u00f3n para finales de 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La solicitud se presenta tras las aprobaciones de AGAMREE en EE. UU. (2023) y la Uni\u00f3n Europea (principios de 2024). Seg\u00fan el Registro Canadiense de Enfermedades Neuromusculares, m\u00e1s de 800 ni\u00f1os y j\u00f3venes en Canad\u00e1 padecen DMD, una enfermedad rara que causa debilidad muscular debido a la falta de la prote\u00edna distrofina.<a href=\"https:\/\/dmdwarrior.com\/es\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" data-type=\"post\" data-id=\"2333\" rel=\"noreferrer noopener\">\u00bfQu\u00e9 es Agamree?<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El desarrollo del f\u00e1rmaco incluy\u00f3 ensayos cl\u00ednicos en cinco centros canadienses, lo que contribuy\u00f3 a su aprobaci\u00f3n global. Organizaciones de pacientes, como Defeat Duchenne Canada y Muscular Dystrophy Canada, han acogido con satisfacci\u00f3n este avance, destacando la actual escasez de tratamientos aprobados en Canad\u00e1.<\/p>","protected":false},"excerpt":{"rendered":"<p>Catalyst Pharmaceuticals has announced that Health Canada has accepted their New Drug Submission (NDS) for AGAMREE (vamorolone) with priority review status for treating Duchenne muscular dystrophy (DMD). If approved, AGAMREE would become the first and only Health Canada-approved therapy for DMD, with potential marketing authorization by the end of 2025. The submission follows AGAMREE&#8217;s approvals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3588,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,171,43],"class_list":["post-3586","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-canada","tag-vamorolone"],"subtitle":"Salud Canad\u00e1 ha concedido a AGAMREE una revisi\u00f3n prioritaria y la autorizaci\u00f3n de comercializaci\u00f3n podr\u00eda concederse antes de finales de 2025.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=3586"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/3588"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=3586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=3586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=3586"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}